Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B | Maissa El Raziky

Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B

Citation:: Raziky, M. E., S. Hamdy, Y. Hamada, N. M. Abdelaziz, M. Hassany, W. Doss, and Z. Zakaria, "Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B", Egyptian Liver Journal, vol. 12, pp. Article number: 11, 2022.